NRG-BN010
Brief description of study
The primary hypothesis of this study is that the combination of tocilizumab, atezolizumab , and FSRT will lead to a robust anti-tumor immune response in GBM. This hypothesis is based on strong preclinical data, which has demonstrated (1) critical roles for IL-6 in GBM immune evasion, (2) that targeting IL-6 with anti-PD-L1 therapy may result in synergistic anti-tumor effects, and (3) that FSRT is capable of inciting multiple immunostimulatory effects in the tumor microenvironment.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
